Richard Eric Mortimer

Learn More
The growing frequency of authorized generics has important implications for the welfare of prescription drug consumers. Authorized generic entry could affect the timing of generic entry, brand-name and generic prices, and generic penetration. We reviewed 1999-2003 data and found that generic entry in the absence of short-run exclusivity restrictions(More)
The evolution of pharmaceutical competition since Congress passed the Hatch-Waxman Act in 1984 raises questions about whether the act's intended balance of incentives for cost savings and continued innovation has been achieved. Generic drug usage and challenges to brand-name drugs' patents have increased markedly, resulting in greatly increased cost savings(More)
We present the DREAM (Data Reverse Engineering and Abstraction Mechanism) method for restructuring program data to meet the changing demands upon it. It is important that data changes are made correctly to avoid undesirable effects on the operation of the program and to minimise effort in maintenance. To facilitate this program transformations are used to(More)
As part of the recently enacted health-care reform legislation in the United States, the US Congress authorized an abbreviated regulatory pathway for the approval of biosimilars (also often described as follow-on biologics)1. Among other provisions, the legislation grants a new innovative biologic (termed pioneer biologic here) 12 years of data exclusivity,(More)
OBJECTIVE To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch and first generic competitors) for new molecular entities (NMEs); likelihood, timing and number of Hatch-Waxman Act Paragraph IV patent challenges; and generic drug penetration. METHODS This study used IMS Health National Sales(More)
OBJECTIVE To provide evidence on recent trends in: (1) market exclusivity periods (MEPs, the time between launch of a brand-name drug and its first generic competitor) for new molecular entities (NMEs); (2) the likelihood and timing of patent challenges under Paragraph IV of the Hatch-Waxman Act; and (3) generic drug penetration. METHODS IMS Health(More)
UNLABELLED Abstract Objective: To investigate the evolving use and expected impact of pay-for-performance (P4P) and risk-based provider reimbursement on patient access to innovative medical technology. METHODS Structured interviews with leading private payers representing over 110 million commercially-insured lives exploring current and planned use of P4P(More)
  • 1